ITGA7 and neoplasm: To obtain further evidence in support of our hypothesis that ITGA7+ cells confer chemoresistance in OSCC tumours, we established a chemoresistant OSCC xenograft model by treating KYSE520 subcutaneously developed tumours in NOD/SCID mice with varying doses of cisplatin from 0 to 5 mg kg−1.